Gain Therapeutics, Inc. - Common Stock (GANX)

Gain Therapeutics reported positive Phase 1 results for GT-02287, showing safety and tolerability across all age groups. The company plans a Parkinson's disease trial by Q4 2024.

GANX stock results show that Gain Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.

Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!

Arm stock is up on Friday and is preparing for a catalyst later this month when it replaces Sirius XM on the Nasdaq 100.

Gain Therapeutics stock is down on Friday after the company priced an $11 million public offering for roughly 7 million shares of GANX.

Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!

GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Gain Therapeutics' GBA1 Parkinson's disease focused GT-02287's mechanism of action, tackling GCase misfolding to enhance lysosomal activity.